Close Menu

NEW YORK (GenomeWeb) – Evercore ISI said today that it has initiated coverage of Twist Bioscience with an Outperform rating and a price target of $30.50.

In a note to investors, Evercore ISI Analyst Ross Muken and colleagues wrote that Twist can likely maintain a growth rate of more than 25 percent over the next three to five years through its DNA synthesis and NGS tools businesses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.